Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need NEW YORK / Jun 27, 2025 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström macroglobulinemia that have failed at least... Read More

NEW YORK / Jun 17, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 13, 2025, the company granted restricted stock units (RSUs) with respect to 10,290 shares of the company’s common stock to five newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a... Read More

SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed across a broad range of B-cell malignancies, including monotherapy responses in patients with CLL and Waldenström macroglobulinemia Management to host a webcast today at 8:00 a.m. ET MILAN / Jun 12, 2025 / Business Wire / Schrödinger... Read More

NEW YORK / May 29, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company’s newly appointed EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing, Mannix Aklian. As previously announced, Mr. Aklian joined the company on May 28, 2025. The grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, as amended, were... Read More

NEW YORK / May 29, 2025 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will... Read More

NEW YORK / May 23, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 21, 2025, the company granted restricted stock units (RSUs) with respect to 7,051 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a... Read More

NEW YORK / May 22, 2025 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference. The live presentation will take place on Wednesday, June 4, 2025 at 1:25 p.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event.... Read More

Richie Jain to succeed Geoffrey Porges as CFO NEW YORK / May 20, 2025 / Business Wire / Schrödinger (Nasdaq: SDGR) today announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as chief financial officer to pursue other opportunities. Richie Jain, who previously served as Schrödinger’s senior vice president, strategic finance and head of corporate and business... Read More

Company to host webcast to review data on Thursday, June 12, 2025 at 8:00 a.m. ET NEW YORK / May 14, 2025 / Business Wire / Schrödinger , Inc. ( Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be... Read More

First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million Initial SGR-1505 Phase 1 Clinical Data to be Presented in June Maintains 2025 Financial Guidance NEW YORK / May 07, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended March 31, 2025. “We are very pleased with Schrödinger’s performance in the first quarter of 2025, with strong software... Read More

NEW YORK / May 05, 2025 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the... Read More

Poster presentations include dose optimization data for novel Wee1/Myt1 co-inhibitor SGR-3515 and the first characterization of SGR-4174, a novel SOS1 inhibitor CHICAGO / Apr 28, 2025 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that... Read More

NEW YORK / Apr 23, 2025 / Business Wire / Schrödinger (Nasdaq: SDGR) will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger... Read More

NEW YORK / Apr 18, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company’s common stock to six newly hired employees. These grants were made pursuant to the company’s... Read More

NEW YORK / Apr 14, 2025 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration’s (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA’s roadmap encourages a number of computational approaches to predict... Read More

Presentations include preclinical data on Wee1/Myt1 inhibitor SGR-3515 and SOS1 inhibitor SGR-4174 NEW YORK / Mar 25, 2025 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25 - 30,... Read More

NEW YORK / Mar 18, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s... Read More

NEW YORK / Mar 10, 2025 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. “Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board,” said Ramy Farid,... Read More

Achieved 2024 Software Revenue of $180.4 Million, a 13.3% Increase Over 2023 Expects Software Revenue Growth of 10% to 15% and Drug Discovery Revenue of $45-50 Million in 2025 Announces Expanded Research Collaboration with Eli Lilly and Company On Track to Report Initial Phase 1 Data from Three Proprietary Programs in 2025 NEW YORK / Feb 26, 2025 / Business Wire / Schrödinger, Inc . (Nasdaq: SDGR) today announced financial... Read More

NEW YORK / Feb 24, 2025 / Business Wire / Schrödinger (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 45th Annual Health Care Conference: Fireside chat on Tuesday, March 4, 2025 at 10:30 a.m. E.T. Leerink Partners Global Biopharma Conference 2025: Fireside chat on Monday, March 10, 2025 at 3:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 18,... Read More

NEW YORK / Feb 20, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today reported that on February 17, 2025, the company granted restricted stock units (RSUs) with respect to 5,445 shares of the company’s common stock to five newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a... Read More

NEW YORK / Feb 12, 2025 / Business Wire / Schrödinger (Nasdaq: SDGR) will report its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event.... Read More

NEW YORK / Jan 22, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today reported that on January 20, 2025, the company granted restricted stock units (RSUs) with respect to 4,840 shares of the company’s common stock to four newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a... Read More

Announces Expanded Research Collaboration Agreement with Otsuka Pharmaceutical Co., Ltd. On Track to Report Initial Phase 1 Data from Three Proprietary Programs in 2025 Focus on Delivering Continued Software Growth and Increased Drug Discovery Revenue NEW YORK / Jan 13, 2025 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic... Read More

NEW YORK / Dec 17, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 12, 2024, the company granted restricted stock units (RSUs) with respect to 8,365 shares of the company’s common stock to six newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a... Read More

NEW YORK / Nov 20, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference. The live presentation will take place on Wednesday, December 4, 2024 at 8:30 a.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following... Read More

NEW YORK / Nov 19, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today reported that on November 14, 2024, the company granted restricted stock units (RSUs) with respect to 2,785 shares of the company’s common stock to four newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a... Read More

Additional funding received from the Bill & Melinda Gates Foundation to further accelerate initiative NEW YORK / Nov 18, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), today announced that it is broadening and accelerating its initiative to expand the company’s computational platform to predict toxicology risk early in drug discovery. The goal of the initiative, announced earlier this year , is to develop a... Read More

Schrödinger to Receive $150 Million Upfront for New Multi-Target Collaboration with Novartis Third Quarter Total Revenue of $35.3 Million, Software Revenue of $31.9 Million Updates 2024 Financial Guidance NEW YORK / Nov 12, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier today,... Read More

Schrödinger to receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties Expanded multi-year software agreement enables technology deployment at significant scale across Novartis’s global research organization Schrödinger to host third quarter 2024 financial results webcast today at 8:00 a.m. ET NEW YORK / Nov 12, 2024 / Business Wire / Schrödinger, Inc.... Read More

NEW YORK / Nov 04, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation will take place on Wednesday, November 20, at 8:30 a.m. GMT (3:30 a.m. ET). The live webcast can be accessed in... Read More

NEW YORK / Oct 31, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third quarter 2024 financial results on Tuesday, November 12, 2024, before the financial markets open. The company will host a conference call and webcast at 8:00 a.m. ET. The live webcast can be accessed in the “Investors” section... Read More

New preclinical data on PRMT5-MTA inhibitor program will also be presented NEW YORK / Oct 23, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that... Read More

NEW YORK / Oct 17, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on October 12, 2024, the company granted (i) a non-statutory stock option to purchase 5,700 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 15,890... Read More

NEW YORK / Oct 09, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and the company’s PRMT5-MTA inhibitor program, will be presented during poster sessions at the 36th EORTC-NCI-AACR Symposium (ENA 2024) taking place October 23-25, 2024 in Barcelona, Spain. The SGR-3515 presentation will include data further characterizing... Read More

NEW YORK / Sep 18, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on September 13, 2024, the company granted restricted stock units (RSUs) with respect to 7,025 shares of the company’s common stock to eight newly hired employees. These grants were made pursuant to the company’s 2021... Read More

NEW YORK / Aug 16, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on August 14, 2024, the company granted restricted stock units (RSUs) with respect to 7,500 shares of the company’s common stock to 13 newly hired employees. These grants were made pursuant to the company’s 2021 Inducement... Read More

NEW YORK / Aug 14, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. The live presentation will take place on Wednesday, September 4, 2024, at 3:20 p.m. ET. The live webcast can be... Read More

Second Quarter Total Revenue of $47.3 Million, Software Revenue of $35.4 Million Launches Major Initiative to Expand Application of Computational Tools for Predictive Toxicology Initial Clinical Data Expected for SGR-1505 in 1H25, SGR-2921 and SGR-3515 Data in 2H25 NEW YORK / Jul 31, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and... Read More

Initiative initially funded by $10 million grant from the Bill & Melinda Gates Foundation NEW YORK / Jul 26, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that it is embarking on an initiative to expand its computational platform to predict toxicology risk early in drug discovery. The goal... Read More

NEW YORK / Jul 17, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section... Read More

NEW YORK / Jul 16, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on July 12, 2024, the company granted restricted stock units (RSUs) with respect to 9,990 shares of the company’s common stock to eight newly hired employees. These grants were made pursuant to the company’s 2021... Read More

NEW YORK / Jun 14, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on June 11, 2024, the company granted (i) a non-statutory stock option to purchase 2,400 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 9,420 shares... Read More

NEW YORK / May 22, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference. The live presentation will take place on Wednesday, June 5, 2024, at 2:30 p.m. ET. The live webcast can be accessed in the “Investors”... Read More

NEW YORK / May 17, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on May 16, 2024, the company granted restricted stock units (RSUs) with respect to 4,090 shares of the company’s common stock to three newly hired employees. These grants were made pursuant to the company’s 2021 Inducement... Read More

First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for Initial Phase 1 Data Readouts in Late 2024 or 2025 NEW YORK / May 01, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics... Read More

NEW YORK / Apr 18, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on April 15, 2024, the company granted (i) non-statutory stock options to purchase 3,600 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 9,613... Read More

NEW YORK / Apr 10, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2024 financial results on Wednesday, May 1, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of... Read More

NEW ORLEANS / Mar 20, 2024 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1 inhibitor, during the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2024 Meeting. SGR-1505 is being evaluated in a Phase 1 dose-escalation study in... Read More

NEW YORK / Mar 19, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on March 15, 2024, the company granted (i) non-statutory stock options to purchase 40,400 shares of the company’s common stock to six newly hired employees and (ii) restricted stock units (RSUs) with respect to 18,550... Read More

Achieved Fourth Quarter Software Revenue of $68.7 Million, a 44% Increase Over Fourth Quarter 2022 Delivered 20% Annual Total Revenue Growth, with Total Revenue of $216.7 Million Expects Software Revenue Growth of 6% to 13% in 2024 NEW YORK / Feb 28, 2024 / Business Wire / Schrödinger, Inc . (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today... Read More

NEW YORK / Feb 20, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the following conferences in March: TD Cowen 44th Annual Health Care Conference: Fireside chat on Tuesday, March 5, 2024 at 10:30 a.m. ET. Leerink Partners Global Biopharma Conference: Fireside... Read More

NEW YORK / Feb 16, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on February 13, 2024, the company granted (i) non-statutory stock options to purchase 4,800 shares of the company’s common stock to four newly hired employees and (ii) restricted stock units (RSUs) with respect to 5,550... Read More

NEW YORK / Feb 14, 2024 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the... Read More

NEW YORK / Jan 19, 2024 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on January 16, 2024, the company granted (i) non-statutory stock options to purchase 6,825 shares of the company’s common stock to seven newly hired employees and (ii) restricted stock units (RSUs) with respect to 8,438... Read More

Announces Expanded Multi-Year Software Agreement with Lilly Continued Focus in 2024 on Advancing Science Underlying Platform, Driving Software Adoption and Progressing Proprietary Pipeline NEW YORK / Jan 08, 2024 / Business Wire / Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update... Read More

UBTech is the first humanoid robot company to go public on HKEx Qiming is UBTech's early institutional investor, exclusively investing in its Series A round in 2015 UBTech's listing is Qiming's eighth IPO in 2023 SHANGHAI , Dec. 29, 2023 /PRNewswire/ -- Qiming Venture Partners' portfolio company UBTech, a humanoid robot leader in China , successfully debuted on the Hong Kong Stock Exchange today. The first humanoid robot... Read More

NEW YORK / Dec 19, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on December 13, 2023, the company granted (i) non-statutory stock options to purchase 1,800 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 2,250... Read More

Reports data showing SGR-1505 is well-tolerated and achieves target engagement in Phase 1 healthy volunteer study Highlights expanding portfolio including newly-disclosed EGFR C797S , PRMT5-MTA and NLRP3 programs Outlines broad discovery and development efforts targeting synthetic lethality and DNA-damage repair mechanisms, including PRMT5-MTA, SGR-3515 and SGR-2921 programs NEW YORK / Dec 14, 2023 / Business Wire /... Read More

NEW YORK / Dec 10, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced new preclinical data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, in a poster session at the American Society of Hematology (ASH) 65th Annual Meeting taking place virtually and... Read More

NEW YORK / Nov 17, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on November 13, 2023, the company granted (i) non-statutory stock options to purchase 14,400 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 10,050... Read More

NEW YORK / Nov 06, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the following conferences in November: Jefferies London Healthcare Conference: Fireside chat on Wednesday, November 15, 2023, at 9:30 a.m. GMT (4:30 a.m. ET). Piper Sandler 35th Annual Healthcare... Read More

NEW YORK / Nov 02, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, will be presented during a poster session at the American Society of Hematology (ASH) 65th Annual Meeting taking place... Read More

Delivers Third Quarter Total Revenue of $42.6 Million; Maintains Full-Year 2023 Revenue Guidance Continued Progress for SGR-1505, Healthy Volunteer Data Expected in Fourth Quarter of 2023 Phase 1 Study Initiated for SGR-2921; Discloses PRMT5-MTA Discovery Program BMS Returns Two Programs From Collaboration NEW YORK / Nov 01, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform... Read More

NEW YORK / Oct 30, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that the company will host its Pipeline Day in New York City on Thursday, December 14, 2023, beginning at 10:00 a.m. ET. Members of the Schrödinger team will provide a detailed review of the company's development programs, including... Read More

NEW YORK / Oct 23, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on October 17, 2023, the company granted (i) non-statutory stock options to purchase 9,150 shares of the company’s common stock to six newly hired employees and (ii) restricted stock units (RSUs) with respect to 11,625... Read More

NEW YORK / Oct 18, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third quarter 2023 financial results on Wednesday, November 1, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in... Read More

NEW YORK / Sep 28, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, and two City University of New York (CUNY) institutions, New York City College of Technology (City Tech) and LaGuardia Community College (LaGuardia), today announced that they have been awarded a three-year, $1M grant from the National Science... Read More

SHANGHAI , Sept. 26, 2023 /PRNewswire/ -- Qiming Venture Partners' portfolio company Tuhu Car, China's leading one-stop car service platform, successfully listed on the Hong Kong Stock Exchange. The issue price of Tuhu Car (SEHK:9690) was HK$28 per share, representing a market capitalization of about HK$ Billion 22.75. As an early investor, Qiming invested in Tuhu Car's Series B, C and E rounds since 2014. The successful IPO... Read More

NEW YORK / Sep 18, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on September 14, 2023, the company granted (i) non-statutory stock options to purchase 8,250 shares of the company’s common stock to six newly hired employees and (ii) restricted stock units (RSUs) with respect to 7,485... Read More

NEW YORK / Sep 05, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference. The live presentation will take place on Tuesday, September 12, 2023, at 2:15 p.m. ET. The live webcast can be... Read More

NEW YORK / Aug 11, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on August 9, 2023, the company granted (i) a non-statutory stock option to purchase 90,000 shares of the company’s common stock and (ii) restricted stock units (RSUs) with respect to 15,000 shares of the company’s common... Read More

Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505 Delivers Second Quarter Total Revenue of $35.2 Million Raises 2023 Software Revenue Guidance and Reduces Drug Discovery Guidance NEW YORK / Aug 02, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today... Read More

NEW YORK / Jul 20, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on July 14, 2023, the company granted (i) non-statutory stock options to purchase 10,250 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 6,225... Read More

NEW YORK / Jul 19, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2023 financial results on Wednesday, August 2, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in... Read More

NEW YORK / Jun 22, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on June 16, 2023, the company granted (i) non-statutory stock options to purchase 14,325 shares of the company’s common stock to 11 newly hired employees and (ii) restricted stock units (RSUs) with respect to 11,138 shares... Read More

NEW YORK / Jun 01, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference. The live presentation will take place on Tuesday, June 13, 2023, at 2:40 p.m. ET. The live discussion can be accessed... Read More

NEW YORK / May 26, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference. The live presentation will take place on Wednesday, June 7, 2023, at 2:30 p.m. ET. The live discussion can be accessed under "News & Events"... Read More

NEW YORK / May 25, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on May 19, 2023, the company granted (i) non-statutory stock options to purchase 7,660 shares of the company’s common stock to five newly hired employees and (ii) restricted stock units (RSUs) with respect to 1,988 shares... Read More

Delivered First Quarter Total Revenue of $64.8 Million, Driven by Strong Drug Discovery Revenue of $32.6 Million Reports First Subjects Enrolled in Both Ongoing Phase 1 Study of MALT1 Inhibitor SGR-1505 and Newly Initiated Phase 1 Study in Healthy Subjects Cash Position Significantly Strengthened by $147.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda NEW YORK / May 04, 2023 / Business Wire /... Read More

Report Highlights Accomplishments in 2022 and Outlines Material Topics Through the Concept of Shared Value NEW YORK / Apr 27, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today published its inaugural Corporate Sustainability Report . The report highlights the company's vision and approach to corporate... Read More

NEW YORK / Apr 20, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2023 financial results on Thursday, May 4, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the... Read More

NEW YORK / Apr 19, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on April 14, 2023, the company granted (i) a non-statutory stock option to purchase 2,400 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSU) with respect to 1,800 shares... Read More

NEW YORK / Mar 22, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on March 19, 2023, the company granted non-statutory stock options to purchase an aggregate of 32,700 shares of the company’s common stock to 10 newly hired employees, including two newly hired employees based outside of... Read More

NEW YORK / Feb 28, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided its financial outlook for 2023. “We are very pleased with our performance across all areas of our business last year, with strong... Read More

NEW YORK / Feb 17, 2023 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on February 15, 2023, the company granted non-statutory stock options to purchase an aggregate of 45,600 shares of the company’s common stock to 11 newly hired employees, including two newly hired employees based outside... Read More

NEW YORK / Feb 14, 2023 / Business Wire / Schrödinger Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported the receipt of an $111.3 million cash distribution from Nimbus Therapeutics, LLC (Nimbus) in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2)... Read More

NEW YORK / Feb 13, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2022 financial results on Tuesday, February 28, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed under "News... Read More

SHANGHAI , Feb. 4, 2023 /PRNewswire/ -- Qiming Venture Partners' portfolio company Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical stage global biopharmaceutical company focusing on novel oral small molecule therapeutics, successfully debuts on Nasdaq on February 3 Beijing Time. It issued at $15 .00 per ADS, opened at $25.00 per ADS and up by 66.67%, representing a market cap of $915 million . As an early investor,... Read More

NEW YORK / Jan 31, 2023 / Business Wire / Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the SVB Securities Global Biopharma Conference and will give a presentation on Tuesday, February 14, 2023, at 1:00 p.m. ET. The live discussion can be accessed under "News & Events" in the... Read More

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on January 16, 2023, the company granted (i) non-statutory stock options to purchase an aggregate of 14,300 shares of the company’s common stock to six newly hired employees, including three newly hired employees based outside of the United States and (ii)... Read More

New Target Added to Ongoing Collaboration with Bristol Myers Squibb Unveils LRRK2 Inhibitor Program Targeting Neurodegenerative Diseases New Collaboration and Software Agreement with Otsuka Pharmaceutical Co., Ltd. Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and... Read More